Literature DB >> 2082311

Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramuscular, and oral administration in humans and animals.

E J Mroszczak1, D Jung, J Yee, L Bynum, H Sevelius, I Massey.   

Abstract

In humans, ketorolac is completely bioavailable and its kinetics are linear. It is absorbed rapidly (half-life for absorption 3.8 min) after oral (fasting) and intramuscular administration; food delays but does not reduce its absorption. The drug is highly protein bound in humans (greater than 99%). The mean plasma elimination half-life is 5-6 hours, and ketorolac is not extensively distributed outside the vascular compartment (Vd beta 15 L). Virtually all of the drug-related material circulating in plasma is in the form of ketorolac (greater than 96%), with the only metabolite the pharmacologically inactive p-hydroxyketorolac (PHK). Humans excrete about 90% of the administered dose in urine. About 60% of drug-related material recovered from urine is ketorolac, about 12% is PHK, and 28% represents polar, glucuronide conjugates of ketorolac. The animal models in which ketorolac's metabolism and kinetics are most similar to those in humans are the mouse and monkey, respectively.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2082311

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  13 in total

1.  Body weight, gender and pregnancy affect enantiomer-specific ketorolac pharmacokinetics.

Authors:  Pyry A Välitalo; Heidi Kemppainen; Aida Kulo; Anne Smits; Kristel van Calsteren; Klaus T Olkkola; Jan de Hoon; Catherijne A J Knibbe; Karel Allegaert
Journal:  Br J Clin Pharmacol       Date:  2017-05-14       Impact factor: 4.335

2.  The impact of pregnancy on urinary ketorolac metabolites after single intravenous bolus.

Authors:  Aida Kulo; Sarah Hendrickx; Jan de Hoon; Nedzad Mulabegovic; Kristel van Calsteren; Rene Verbesselt; Karel Allegaert
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-11-21       Impact factor: 2.441

3.  Perioperative effects of oral ketorolac and acetaminophen in children undergoing bilateral myringotomy.

Authors:  M F Watcha; M Ramirez-Ruiz; P F White; M B Jones; R G Lagueruela; R P Terkonda
Journal:  Can J Anaesth       Date:  1992-09       Impact factor: 5.063

Review 4.  Clinical pharmacokinetics of ketorolac tromethamine.

Authors:  D R Brocks; F Jamali
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

5.  Effect of food on systemic exposure to niflumic acid following postprandial administration of talniflumate.

Authors:  Wonku Kang; Kibum Kim; Eun-Young Kim; Kwang-il Kwon; Jun Seok Bang; Young-Ran Yoon
Journal:  Eur J Clin Pharmacol       Date:  2008-07-08       Impact factor: 2.953

6.  Effect of Oral Premedication on the Efficacy of Inferior Alveolar Nerve Block in Patients with Symptomatic Irreversible Pulpitis: A Prospective, Double-Blind, Randomized Controlled Clinical Trial.

Authors:  Suparna Ganguly Saha; Sohini Jain; Sandeep Dubey; Shubham Kala; Abhinav Misuriya; Devendra Kataria
Journal:  J Clin Diagn Res       Date:  2016-02-01

Review 7.  Nonopioid analgesics for perioperative and cardiac surgery pain in children: Current evidence and knowledge gaps.

Authors:  Ashish Saini; Kevin O Maher; Shriprasad R Deshpande
Journal:  Ann Pediatr Cardiol       Date:  2019-12-04

8.  Injectable Ketorolac and Corticosteroid Use in Athletes: A Systematic Review.

Authors:  Timothy R Jelsema; Anthony C Tam; James L Moeller
Journal:  Sports Health       Date:  2020-09-02       Impact factor: 3.843

9.  Letter to the editor.

Authors:  David B Bregman
Journal:  Sports Health       Date:  2013-03       Impact factor: 3.843

10.  Letter to the editor response.

Authors:  Matthew Matava; D Craig Brater; Nancy Gritter; Robert Heyer; Douglas Rollins; Theodore Schlegel; Robert Toto; Anthony Yates
Journal:  Sports Health       Date:  2013-03       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.